Pharmaceutical Technology-10-01-2019

Pharmaceutical Technology

Proactive Evaluation of Possible Genotoxic Impurities During the Early Stages of Drug Development

October 02, 2019

Features

2019 Supplement

5

The author provides a direction for identifying genotoxic impurities early in the drug development process, regulating genotoxic impurities at acceptable levels in the API or drug product, and avoiding negative product regulation late in the development and/or marketing process, including expensive recalls.

How Excipient Type Influences Self-Emulsifying Drug Delivery

October 01, 2019

Features

2019 Supplement

5

High-throughput platforms can be used to develop tertiary phase diagrams, which can be leveraged to identify the most stable SEDDS formulations and excipients for lipid-based drug delivery systems.

Perspectives on Quality Attributes of Drug Products Containing Nanomaterials

October 01, 2019

Features

2019 Supplement

5

In this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.

Pharmaceutical Technology North America, APIs, Excipients, and Manufacturing 2019 Supplement (PDF)

October 01, 2019

Issue PDF

2019 Supplement

5

Click the title above to open the Pharmaceutical Technology APIs, Excipients, and Manufacturing 2019 in an interactive PDF format.